Human Milk Oligosaccharides (HMO) Market by Type (2’ Fl, 3’ Fl, 3’ Sl, 6’ Sl), Application (Infant Formula, Functional Food & Beverages, Food Supplement), Concentration (Acidic, Neutral), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
The global Human Milk Oligosaccharides (HMO) Market size is projected to reach a CAGR of 23.4% from 2023-2030.
Human milk oligosaccharides, also known as human milk glycans, are short polymers of simple sugars that can be found in high concentrations exclusively in human breast milk. Human milk oligosaccharides promote the development of the immune system, can reduce pathogen infections, and improve brain development and cognition. Approximately 200 structurally different human milk oligosaccharides are known and the exact composting of these varies from mother to mother.
The functional benefits of these products have created a huge demand for the biosynthetic production of HMOs for use as additives in infant formulas and other dietary products. HMO molecules can be produced chemically, through fermentation, or through enzymatic synthesis. Moreover, the surge in demand for HMOs has increased the utilization of various nutritional products used as food or dietary supplements. One of the major factors and Human Milk Oligosaccharides (HMO) market trends that boosts the Human Milk Oligosaccharides (HMO) market growth is the availability of new technologies such as enzymatic trans-glycosylation, which is used for artificially synthesizing the HMOs. Other major factors driving the demand for HMOs around the world include improvement in lifestyle and rise in concerns about health & wellness. Furthermore, HMOs in food supplements and functional food and beverage products can aid in the treatment of specific disorders and high-risk health conditions, which is acts as a key driving force of the global Human Milk Oligosaccharides (HMO) market. This has created Human Milk Oligosaccharides (HMO) market opportunity. However, high costs associated with the product is expected to pose a challenge for the growth of the market during Human Milk Oligosaccharides (HMO) market forecast.
On the other hand, the absence of technologies for large-scale manufacturing, the massive price of research and development, and the rigorous federal regulations are all expected to limit the expansion of the HMO industry. Additionally, it is possible that the high prices connected with the goods would hinder market expansion throughout the projection period.
The COVID-19 pandemic had a significant impact on the Human Milk Oligosaccharides (HMO) market. The demand for HMO increased during the lockdown due to panic buying for at-home consumption during the initial phase of the pandemic. As a result, the sales of HMOs escalated during the pandemic, due to the fact that it serves as an immunity booster.
The demand for infant formula-containing HMOs and increased awareness of the health advantages of HMOs are driving the growth and dynamism of the human milk oligosaccharides (HMO) market. While there are now many competitors operating in the industry, it is fragmented, and there are some consolidations as larger businesses want to increase their offers and acquire a competitive edge. Regulatory oversight of the market is also present, notably in relation to the efficacy and safety of HMOs used in baby formula. Overall, it is anticipated that the HMO market will expand over the upcoming years as a result of growing demand from emerging nations and ongoing studies into the health advantages of HMOs.
Asia Pacific to Dominate the Market
Report Feature |
Descriptions |
---|---|
Growth Rate |
CAGR of 22.9% during the forecasting period, 2023-2030 |
Historical Data |
2019-2021 |
Forecast Years |
2023-2030 |
Base Year |
2022 |
Units Considered |
Revenue in USD million and CAGR from 2023 to 2030 |
Report Segmentation |
Type, application, concentration, and region. |
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and Middle East, and Africa |
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, and South Africa (50+ Countries Across the Globe) |
Companies Profiled |
Abbott Laboratories, BASF S.E., Biosynth Carbosynth, Chr. Hansen Holding A/S, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Elicityl S.A., Glycom A/S, Glycosyn, Inbiose NV, Medolac Laboratories, Neolacta Lifesciences Pvt. Ltd, Nestle Health Science, Royal DSM, and ZuChem. |
Available Customization |
In addition to the market data for Human Milk Oligosaccharides (HMO) Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirement. |
Human Milk Oligosaccharides (HMO) Market is segmented into various segments such as type, application, concentration and region:
On the basis of type
On the basis of application
On the basis of concentration
On the basis of region
The prominent players in Human Milk Oligosaccharides (HMO) Market are